Bank of Japan Officials Signal Continued Interest Rate Hikes Amid Inflation Concerns 
Democratic Attorneys General Sue Trump Administration Over CDC Childhood Vaccine Schedule Changes 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
WTO Reform Talks Begin in Cameroon Amid Global Trade Tensions 
SpaceX Starship Explodes in Texas During Test, Citing Nitrogen Tank Failure 
Dollar Strengthens as U.S.-Iran Peace Talks Send Mixed Signals 
Google's TurboQuant Algorithm Sends Memory Chip Stocks Tumbling 
Lynas Rare Earths Signs Vietnam Deal with LS Eco Energy to Boost Magnet Metal Production 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Trump Signs Executive Order to Boost AI Research in Childhood Cancer 
Gold Prices Drop Amid Iran Peace Talk Uncertainty and Stronger Dollar 
CDC Vaccine Review Sparks Controversy Over Thimerosal Study Citation 
Nanya Technology Shares Surge 10% After $2.5 Billion Private Placement from Sandisk and Cisco 
Fujirebio Holding is now doubling down on developing blood tests to detect Alzheimer’s against which blockbuster therapy is expected soon.
The tiny Tokyo-based diagnostics firm, a unit of H.U. Group Holdings, which has a market value of $1.2 billion, developed the first US-approved spinal fluid test for Alzheimer’s.
According to Goki Ishikawa, the CEO of Fujirebio, the firm is boosting its lineup of reagents used to detect Alzheimer’s biomarkers in blood tests. It aims to file these tests for approval in the US as early as 2023.
Ishikawa said that the lineups offered by industry leaders are still limited, so they are rushing to create a solid lineup of tests.
